Therefore, it may be hypothesized that compounds with reversal MDR efficacy for both the ABCG2 and ABCB1 transporters could produce additional therapeutic benefits in CRC patients receiving chemotherapy anticancer drugs that are substrates for these transporters. The gene discussed is ABCG2; the disease is colorectal carcinoma.